{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:40:42Z","timestamp":1761489642133},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"vor","delay-in-days":916,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1593\/neo.111112","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T13:07:56Z","timestamp":1429794476000},"page":"1058-1068","source":"Crossref","is-referenced-by-count":10,"title":["The Jak2 Inhibitor, G6, Alleviates Jak2-V617F\u2013Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow"],"prefix":"10.1016","volume":"13","author":[{"given":"Annet","family":"Kirabo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung O.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurima","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghanath","family":"Gali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary K.","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather L.","family":"Wamsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhizhuang Joe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Cogle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirpal S.","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Sayeski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1593\/neo.111112_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.2830300411","article-title":"Reversal of bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders","volume":"30","author":"Talarico","year":"1989","journal-title":"Am J Hematol"},{"key":"10.1593\/neo.111112_bib2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.111112_bib3","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1593\/neo.111112_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.111112_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.leu.2404048","article-title":"Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution","volume":"20","author":"Cervantes","year":"2006","journal-title":"Leukemia"},{"key":"10.1593\/neo.111112_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1593\/neo.111112_bib7","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.exphem.2006.07.004","article-title":"Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia","volume":"34","author":"Wang","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1593\/neo.111112_bib9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V96.4.1342","article-title":"Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis","volume":"96","author":"Schmitt","year":"2000","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib10","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","article-title":"Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1593\/neo.111112_bib12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1593\/neo.111112_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1593\/neo.111112_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.blre.2010.10.004","article-title":"JAK2 inhibitors: what\u2019s the true therapeutic potential?","volume":"25","author":"Santos","year":"2011","journal-title":"Blood Rev"},{"key":"10.1593\/neo.111112_bib15","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.bmcl.2009.04.138","article-title":"Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening","volume":"19","author":"Kiss","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1593\/neo.111112_bib16","doi-asserted-by":"crossref","first-page":"31399","DOI":"10.1074\/jbc.M110.168211","article-title":"Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core","volume":"285","author":"Majumder","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1593\/neo.111112_bib17","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1074\/jbc.M110.200774","article-title":"The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F\u2013mediated human pathological cell growth in vitro and in vivo","volume":"286","author":"Kirabo","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1593\/neo.111112_bib18","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/01926230600939971","article-title":"Enhanced histopathology of the bone marrow","volume":"34","author":"Elmore","year":"2006","journal-title":"Toxicol Pathol"},{"key":"10.1593\/neo.111112_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.blre.2011.06.002","article-title":"JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective","volume":"25","author":"Tefferi","year":"2011","journal-title":"Blood Rev"},{"key":"10.1593\/neo.111112_bib21","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib22","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib23","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"10.1593\/neo.111112_bib24","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1593\/neo.111112_bib25","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1021\/jf030073c","article-title":"Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells","volume":"51","author":"Larrosa","year":"2003","journal-title":"J Agric Food Chem"},{"key":"10.1593\/neo.111112_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mnfr.200400094","article-title":"Resveratrol and breast cancer chemoprevention: molecular mechanisms","volume":"49","author":"Le Corre","year":"2005","journal-title":"Mol Nutr Food Res"},{"key":"10.1593\/neo.111112_bib27","first-page":"37","article-title":"New anticancer agents: in vitro and in vivo evaluation of the antitumor and antimetastatic actions of various compounds isolated from medicinal plants","volume":"19","author":"Kimura","year":"2005","journal-title":"In Vivo"},{"key":"10.1593\/neo.111112_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0009-8981(95)06045-1","article-title":"The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease","volume":"235","author":"Pace-Asciak","year":"1995","journal-title":"Clin Chim Acta"},{"key":"10.1593\/neo.111112_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0006-291X(89)91060-7","article-title":"Piceatannol (3,4,3\u2032,5\u2032-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor","volume":"165","author":"Geahlen","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1593\/neo.111112_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkg306","article-title":"Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)\u2013associated diseases","volume":"52","author":"Swanson-Mungerson","year":"2003","journal-title":"J Antimicrob Chemother"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558611800928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558611800928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T07:14:49Z","timestamp":1598944489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558611800928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1476558611800928"],"URL":"https:\/\/doi.org\/10.1593\/neo.111112","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}